Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3314814 · 1 trial · 1 indication
Absolute bioavailability was quantified using a mixed-effects analysis of variance (ANOVA) model applied to the log-transformed dose-normalized AUC(0-∞) of LY3314814 oral dosing and IV administered \[13C415N3\]-LY3314814.
| Arm | Type | Description |
|---|---|---|
| LY3314814 | EXPERIMENTAL | Single 50 milligram (mg) dose of LY3314814 administered orally |
| [13C415N3] LY3314814 | EXPERIMENTAL | Single 100 micrograms (μg) intravenous (IV) dose of \[13C415N3\] LY3314814 administered as an IV infusion. |
| Name | Type | Description |
|---|---|---|
| LY3314814 | DRUG | Administered orally |
| [13C415N3] LY3314814 | DRUG | Administered as an IV infusion |
Inclusion Criteria: * Are overtly healthy males or females * Have venous access sufficient to allow for blood sampling and intravenous (IV) administration of the investigational product Exclusion Criteria: * Have a history of significant ophthalmic disease * Have vitiligo or any other clinically ...
LY3314814 is an investigational small molecule being developed by AstraZeneca PLC (AZN). It is currently in Phase 1 clinical development. The drug has been studied in healthy participants, and its therapeutic area is classified as Other.
LY3314814 is being studied for use in healthy participants. It is an investigational small molecule in Phase 1 clinical development. The drug has not been approved for any medical condition and is still in early-stage clinical trials.
LY3314814 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker symbol AZN. The drug is currently in Phase 1 clinical development.
LY3314814 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied in healthy participants as part of early-stage clinical trials.
LY3314814 has one completed clinical trial, NCT03222427, titled "A Study of LY3314814 in Healthy Participants." This Phase 1 trial was conducted in the United Kingdom and enrolled 8 healthy volunteers. The trial is now completed.